Attached files
| file | filename |
|---|---|
| EX-32.2 - EXHIBIT 32.2 - Arbutus Biopharma Corp | exhibit322_soxcertcfo.htm |
| EX-31.2 - EXHIBIT 31.2 - Arbutus Biopharma Corp | exhibit312_10-kcertcfo.htm |
| EX-31.1 - EXHIBIT 31.1 - Arbutus Biopharma Corp | exhibit311_10-kcertceo.htm |
| EX-23.1 - EXHIBIT 23.1 - Arbutus Biopharma Corp | exhibit231_kpmg.htm |
| EX-21.1 - EXHIBIT 21.1 - Arbutus Biopharma Corp | exhibit211_listingofsubsid.htm |
| EX-10.77 - EXHIBIT 10.77 - Arbutus Biopharma Corp | exhibit1077_koertvandenend.htm |
| EX-10.76 - EXHIBIT 10.76 - Arbutus Biopharma Corp | exhibit1076_koertvandenend.htm |
| EX-10.75 - EXHIBIT 10.75 - Arbutus Biopharma Corp | exhibit1075_brucecousinscf.htm |
| EX-3.1 - EXHIBIT 3.1 - Arbutus Biopharma Corp | exhibit31_articlesandartic.htm |
| 10-K - 10-K - Arbutus Biopharma Corp | arbutus10k2017.htm |
Exhibit 32.1
CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO SECTION 906
OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Annual Report of Arbutus Biopharma Corporation (the “Company”) on Form 10-K for the year ended December 31, 2017, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I Mark J. Murray, President and Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:
1. | The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and |
2. | The information contained in the Report fairly represents, in all material respects, the financial condition and results of the operations of the Company. |
Date: March 15, 2018
/s/ Mark J. Murray | |||
Name: | Mark J. Murray | ||
Title: | President and Chief Executive Officer | ||